Role of antiplatelet therapy in cardiovascular disease II: Ischemic stroke

Authors: Jeffrey J. Cavendish¹; Steven C. Cramer²; Glenn D. Graham³

Source: Current Medical Research and Opinion, Volume 20, Number 11, November 2004 , pp. 1845-1849(5)

Buy & download fulltext article:

Price: $51.50 plus tax (Refund Policy)

Abstract:

The etiology of cerebrovascular disease is heterogeneous, with the majority of strokes being of ischemic origin. Transient ischemic attack is now considered to be an important precursor and long-term risk factor for ischemic stroke. Given the lack of acute therapies for ischemic stroke, current treatments focus on secondary prevention through risk-factor management, pharmacotherapy and interventional approaches. As illustrated in this paper, antiplatelet agents (e.g. clopidogrel, aspirin, dipyridamole) are the cornerstone of therapy for prevention of recurrent ischemic stroke.

Keywords: ANTIPLATELET; ATHEROTHROMBOSIS; ISCHEMIC STROKE; TRANSIENT ISCHEMIC ATTACK

Document Type: Research article

DOI: http://dx.doi.org/10.1185/030079904X10674

Affiliations: 1: Department of Cardiology, Naval Medical Center, San Diego, CA, USA 2: Departments Neurology and Anatomy and Neurobiology, UCI Medical Center, University of California Irvine, Orange, CA, USA 3: Departments of Neurology, Radiology, and Neurosciences, Albuquerque VA and Neurology/127, VA Medical Center, University of New Mexico School of Medicine, Albuquerque, NM, USA

Publication date: 2004-11-01

More about this publication?